Analysts expect that Senseonics Holdings Inc (NASDAQ:SENS) will announce sales of $1.51 million for the current quarter, Zacks reports. Two analysts have provided estimates for Senseonics Holdings’ earnings, with estimates ranging from $1.51 million to $1.52 million. Senseonics Holdings reported sales of $40,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 3,675%. The company is scheduled to report its next earnings report after the market closes on Tuesday, October 31st.

According to Zacks, analysts expect that Senseonics Holdings will report full-year sales of $1.51 million for the current fiscal year, with estimates ranging from $5.60 million to $6.15 million. For the next year, analysts anticipate that the firm will post sales of $33.46 million per share, with estimates ranging from $27.00 million to $39.91 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Senseonics Holdings.

Senseonics Holdings (NASDAQ:SENS) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $0.81 million during the quarter, compared to analyst estimates of $0.81 million.

Several research firms recently weighed in on SENS. Canaccord Genuity restated a “buy” rating on shares of Senseonics Holdings in a research report on Thursday, September 28th. Zacks Investment Research upgraded shares of Senseonics Holdings from a “sell” rating to a “hold” rating in a research report on Tuesday, August 15th.

Shares of Senseonics Holdings (NASDAQ:SENS) opened at 2.43 on Tuesday. Senseonics Holdings has a 1-year low of $1.26 and a 1-year high of $3.67. The firm’s market capitalization is $299.38 million. The stock has a 50 day moving average of $3.02 and a 200-day moving average of $3.02.

In other Senseonics Holdings news, COO Mukul Jain sold 11,885 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $3.25, for a total transaction of $38,626.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

A number of hedge funds and other institutional investors have recently modified their holdings of SENS. Raymond James Financial Services Advisors Inc. bought a new position in Senseonics Holdings during the first quarter valued at approximately $147,000. Renaissance Technologies LLC bought a new position in Senseonics Holdings during the first quarter valued at approximately $111,000. ING Groep NV grew its position in Senseonics Holdings by 87.7% during the second quarter. ING Groep NV now owns 225,833 shares of the company’s stock valued at $406,000 after acquiring an additional 105,494 shares during the last quarter. NEA Management Company LLC grew its position in Senseonics Holdings by 27.1% during the second quarter. NEA Management Company LLC now owns 33,425,275 shares of the company’s stock valued at $60,165,000 after acquiring an additional 7,119,989 shares during the last quarter. Finally, LMR Partners LLP bought a new position in Senseonics Holdings during the second quarter valued at approximately $177,000.

TRADEMARK VIOLATION NOTICE: “$1.51 Million in Sales Expected for Senseonics Holdings Inc (SENS) This Quarter” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/24/1-51-million-in-sales-expected-for-senseonics-holdings-inc-sens-this-quarter-2.html.

About Senseonics Holdings

Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.

Get a free copy of the Zacks research report on Senseonics Holdings (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senseonics Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.